학술논문
Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges
Document Type
article
Author
Schrom, John; Marquez, Carina; Wang, Chung-Yu; Saxena, Aditi; Mitchell, Anthea M; Ribeiro, Salu; Pilarowski, Genay; Nakamura, Robert; Rojas, Susana; Black, Douglas; Oseguera, Maria G Contreras; Diaz, Edgar Castellanos; Payan, Joselin; Rojas, Susy; Jones, Diane; Tulier-Laiwa, Valerie; Zavaleta, Aleks; Martinez, Jacqueline; Chamie, Gabriel; Glaser, Carol; Jacobson, Kathy; Petersen, Maya; DeRisi, Joseph; Havlir, Diane V
Source
PLOS ONE. 18(3)
Subject
Language
Abstract
COVID-19 oral treatments require initiation within 5 days of symptom onset. Although antigen tests are less sensitive than RT-PCR, rapid results could facilitate entry to treatment. We collected anterior nasal swabs for BinaxNOW and RT-PCR testing and clinical data at a walk-up, community site in San Francisco, California between January and June 2022. SARS-CoV-2 genomic sequences were generated from positive samples and classified according to subtype and variant. Monte Carlo simulations were conducted to estimate the expected proportion of SARS-CoV-2 infected persons who would have been diagnosed within 5 days of symptom onset using RT-PCR versus BinaxNOW testing. Among 25,309 persons tested with BinaxNOW, 2,799 had concomitant RT-PCR. 1137/2799 (40.6%) were SARS-CoV-2 RT-PCR positive. We identified waves of predominant omicron BA.1, BA.2, BA.2.12, BA.4, and BA.5 among 720 sequenced samples. Among 1,137 RT-PCR positive samples, 788/1137 (69%) were detected by BinaxNOW; 94% (669/711) of those with Ct value